Disease Domain | Count |
---|---|
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Hematopoietic stem cell therapy | 1 |
Mesenchymal stem cell therapy | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism Stem cell replacements |
Active Org. |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest PhasePhase 1/2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Apr 2024 |
Sponsor / Collaborator |
Start Date26 Mar 2024 |
Sponsor / Collaborator |
Start Date01 Mar 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
MSC11FCD | Glioblastoma More | Phase 2 Clinical |
Allogeneic cord blood transplantation(Bundang CHA Hospital) | Brain Diseases More | Phase 2 |